OPG/OPGL in highly purified myeloma cells
| Patient . | Age, y . | Sex . | Type . | PC% . | Status . | Osteolysis . | HyperCa . | OPGL mRNA . | OPG mRNA . | OPG ng/mL . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | F | Gκ | 35 | S-PCL | + | ? | − | − | ND |
| 2 | 56 | F | Gκ | 58 | D | + | + | − | − | ? |
| 3 | 64 | M | Gκ | 70 | P-PCL | − | − | − | − | ND |
| 4 | 68 | M | Aκ | 55 | D | − | − | − | − | ND |
| 5 | 49 | M | Gκ | 35 | P-PCL | + | + | − | + | ? |
| 6 | 67 | F | Gλ | 8 | R | + | − | − | − | ND |
| 7 | 75 | M | Gλ | 14 | D | − | − | − | − | ? |
| 8 | 63 | F | Aκ | 20 | D | + | − | − | − | ND |
| 9 | 78 | M | Gλ | 12 | D | + | − | − | − | ND |
| 10 | 58 | F | Aκ | 45 | D | + | + | − | − | ? |
| 11 | 46 | M | Gκ | 50 | D | + | − | − | − | ND |
| 12 | 72 | M | Aκ | 30 | D | − | − | − | − | ND |
| 13 | 60 | M | κ | 46 | P-PCL | + | + | − | − | ND |
| 14 | 81 | F | Gκ | 30 | D | + | + | − | − | ND |
| 15 | 63 | M | Aκ | 45 | P-PCL | − | − | − | − | ND |
| 16 | 71 | M | κ | 30 | R | + | − | − | − | ND |
| 17 | 65 | F | Gκ | 40 | R | − | − | − | − | ND |
| 18 | 43 | F | λ | 27 | D | − | − | − | − | ND |
| 19 | 76 | F | κ | 20 | D | − | − | − | − | ND |
| 20 | 64 | M | Gκ | 20 | R | + | − | − | + | 0.28 |
| 21 | 60 | M | Gλ | 17 | R | + | + | − | − | ND |
| 22 | 63 | M | A | 13 | R | − | − | − | − | ND |
| 23 | 77 | F | Gκ | 45 | D | − | − | − | − | ND |
| 24 | 81 | M | Aκ | 30 | D | + | − | − | − | ND |
| 25 | 65 | M | Gλ | 10 | D | − | − | − | + | 0.52 |
| 26 | 52 | F | Gκ | 50 | D | + | − | − | − | ND |
| Patient . | Age, y . | Sex . | Type . | PC% . | Status . | Osteolysis . | HyperCa . | OPGL mRNA . | OPG mRNA . | OPG ng/mL . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | F | Gκ | 35 | S-PCL | + | ? | − | − | ND |
| 2 | 56 | F | Gκ | 58 | D | + | + | − | − | ? |
| 3 | 64 | M | Gκ | 70 | P-PCL | − | − | − | − | ND |
| 4 | 68 | M | Aκ | 55 | D | − | − | − | − | ND |
| 5 | 49 | M | Gκ | 35 | P-PCL | + | + | − | + | ? |
| 6 | 67 | F | Gλ | 8 | R | + | − | − | − | ND |
| 7 | 75 | M | Gλ | 14 | D | − | − | − | − | ? |
| 8 | 63 | F | Aκ | 20 | D | + | − | − | − | ND |
| 9 | 78 | M | Gλ | 12 | D | + | − | − | − | ND |
| 10 | 58 | F | Aκ | 45 | D | + | + | − | − | ? |
| 11 | 46 | M | Gκ | 50 | D | + | − | − | − | ND |
| 12 | 72 | M | Aκ | 30 | D | − | − | − | − | ND |
| 13 | 60 | M | κ | 46 | P-PCL | + | + | − | − | ND |
| 14 | 81 | F | Gκ | 30 | D | + | + | − | − | ND |
| 15 | 63 | M | Aκ | 45 | P-PCL | − | − | − | − | ND |
| 16 | 71 | M | κ | 30 | R | + | − | − | − | ND |
| 17 | 65 | F | Gκ | 40 | R | − | − | − | − | ND |
| 18 | 43 | F | λ | 27 | D | − | − | − | − | ND |
| 19 | 76 | F | κ | 20 | D | − | − | − | − | ND |
| 20 | 64 | M | Gκ | 20 | R | + | − | − | + | 0.28 |
| 21 | 60 | M | Gλ | 17 | R | + | + | − | − | ND |
| 22 | 63 | M | A | 13 | R | − | − | − | − | ND |
| 23 | 77 | F | Gκ | 45 | D | − | − | − | − | ND |
| 24 | 81 | M | Aκ | 30 | D | + | − | − | − | ND |
| 25 | 65 | M | Gλ | 10 | D | − | − | − | + | 0.52 |
| 26 | 52 | F | Gκ | 50 | D | + | − | − | − | ND |
PC% indicates plasma cell percentage; OPGL, osteoprotegerin ligand; OPG, osteoprotegerin; F, female; S-PCL, secondary plasma cell leukemia; +, present; ?, not determined; −, absent; ND, not detectable; D, multiple myeloma at the diagnosis; M, male; P-PCL, primary plasma cell leukemia; and R, multiple myeloma relapse.